Drug Trial Radar · NCT04450693
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Nov 20, 2020
Primary completion
Mar 24, 2025
Study completion Mar 24, 2025
Sponsor
- Lead sponsor
- BioTissue Holdings, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.
Conditions
- Diabetic Foot Infection
- Non-healing Wound
- Non-healing Diabetic Foot Ulcer
Interventions
TTAX01Biological
TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
Standard careOther
Standard care is defined in this protocol to consist of the following: * Debridement; * Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; * Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; * A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; * Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, * Appropriate use of systemic antibiotics.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete wound healingTime frame: over 25 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
LakeView Clinical Research
Guntersville, Alabama
Banner University Medical Center Tucson
Tucson, Arizona
Clemente Clinical Research
Los Angeles, California
VA Northern California Health Care System
Mather, California
CureCentric
Palmdale, California
PIH Health
Whittier, California
Midland Florida Clinical Research Center
DeLand, Florida
Delray Physician Care Center
Delray Beach, Florida
Gateway Clinical Trials, LLC
O'Fallon, Illinois
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Reno Orthopedic Clinic
Reno, Nevada
Curalta Foot and Ankle
Westwood, New Jersey
Cutting Edge Research, LLC
Circleville, Ohio
University of Texas Southwestern Medical Center
Dallas, Texas
Advantage Foot Care of Houston
Houston, Texas
Biolife Genetics Research
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.